ViewReleaseInStandardHtml

ExpreS2ion Biotech Holding AB: Last day of trading in BTA

In August 2017, ExpreS2ion Biotech Holding AB (”ExpreS2ion”) conducted a rights issue of shares in which the public was also invited to subscribe for shares. Through the rights issue, 872 873 new shares were issued. The last day of trading in BTA (“Betald tecknad aktie”) is September 21, 2017 and the stop day is September 25, 2017.

872 873 new shares have been registered at the Swedish Company Authority (“Bolagsverket”) and these are expected to be distributed to the respective VP account/depot on September 27, 2017. Following registration, the total number of shares in ExpreS2ion amounts to 9 601 612 and the share capital is 1 066 845.7778 SEK.  

Financial advisor and Certified Adviser

Sedermera Fondkommission is the financial advisor to ExpreS2ion in connection with the rights issue. Sedermera Fondkommission is also appointed as Certified Adviser for ExpreS2ion.

For questions related to the rights issue, please contact:

Sedermera Fondkommission

Telephone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se 

For further information, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This information is information that ExpreS2ion Biotech Holding AB is obliged to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 18, 2017.

ExpreS2ion Biotechnologies ApS, is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique platform technology, ExpreS2, enabling cost effective development and robust production of complex proteins for new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the company has used its patented ExpreS2platform to produce more than 250 proteins in collaborations with research institutions and biopharmaceutical companies, with a superior efficiency and success rate.